11 results on '"Nakanishi, Yoichi"'
Search Results
2. A propensity score-matched analysis of the impact of statin therapy on the outcomes of patients with non-small-cell lung cancer receiving anti-PD-1 monotherapy: a multicenter retrospective study
- Author
-
Takada, Kazuki, Shimokawa, Mototsugu, Takamori, Shinkichi, Shimamatsu, Shinichiro, Hirai, Fumihiko, Tagawa, Tetsuzo, Okamoto, Tatsuro, Hamatake, Motoharu, Tsuchiya-Kawano, Yuko, Otsubo, Kohei, Inoue, Koji, Yoneshima, Yasuto, Tanaka, Kentaro, Okamoto, Isamu, Nakanishi, Yoichi, and Mori, Masaki
- Published
- 2022
- Full Text
- View/download PDF
3. Risk factors for disease progression in Japanese patients with COVID-19 with no or mild symptoms on admission
- Author
-
Ninomiya, Toshifumi, Otsubo, Kohei, Hoshino, Teppei, Shimokawa, Mototsugu, Nakazawa, Megumi, Sato, Yoriko, Mikumo, Hironori, Kawakami, Satoru, Mizusaki, Shun, Mori, Yusuke, Arimura, Hidenobu, Tsuchiya-Kawano, Yuko, Inoue, Koji, Uchida, Yujiro, and Nakanishi, Yoichi
- Published
- 2021
- Full Text
- View/download PDF
4. Effects of cigarette smoke on barrier function and tight junction proteins in the bronchial epithelium: protective role of cathelicidin LL-37
- Author
-
Tatsuta, Miyoko, Kan-o, Keiko, Ishii, Yumiko, Yamamoto, Norio, Ogawa, Tomohiro, Fukuyama, Satoru, Ogawa, Aimi, Fujita, Akitaka, Nakanishi, Yoichi, and Matsumoto, Koichiro
- Published
- 2019
- Full Text
- View/download PDF
5. Mast cells contribute to double-stranded RNA-induced augmentation of airway eosinophilia in a murine model of asthma.
- Author
-
Keiko, Kan-o., Matsunaga, Yuko, Fukuyama, Satoru, Moriwaki, Atsushi, Hirai-Kitajima, Hiroko, Yokomizo, Takehiko, Aritake, Kosuke, Urade, Yoshihiro, Nakanishi, Yoichi, Inoue, Hiromasa, and Matsumoto, Koichiro
- Subjects
MAST cells ,EOSINOPHILIA ,DOUBLE-stranded RNA ,IMMUNE response ,ALLERGENS ,NATURAL immunity ,ANIMAL models of asthma - Abstract
Background: Clinical studies showed the contribution of viral infection to the development of asthma. Although mast cells have multiple roles in the pathogenesis of allergic asthma, their role of in the virus-associated pathogenesis of asthma remains unknown. Most respiratory viruses generate double-stranded (ds) RNA during their replication. dsRNA provokes innate immune responses. We recently showed that an administration of polyinocinic polycytidilic acid (poly IC), a mimetic of viral dsRNA, during allergen sensitization augments airway eosinophilia and hyperresponsiveness in mice via enhanced production of IL-13. Methods: The effect of poly IC on allergen-induced airway eosinophilia was investigated for mast cell-conserved Kit
+/+ mice and -deficient KitW /KitW-v mice. The outcome of mast cell reconstitution was further investigated. Results: Airway eosinophilia and IL-13 production were augmented by poly IC in Kit+/+ mice but not in KitW /KitW-v mice. When KitW /KitW-v mice were reconstituted with bone marrow-derived mast cells (BMMCs), the augmentation was restored. The augmentation was not induced in the mice systemically deficient for TIR domain-containing adaptor-inducing IFN-β (TRIF) or interferon regulatory factor (IRF)-3, both mediate dsRNA-triggered innate immune responses. The augmentation was, however, restored in KitW/KitW-v mice reconstituted with TRIF-deficient or IRF-3-deficient BMMCs. Alt hough leukotriene B4 and prostaglandin D2 are major lipid mediators released from activated mast cells, no their contribution was shown to the dsRNA-induced augmentation of airway eosinophilia. Conclusions: We conclude that mast cells contribute to dsRNA-induced augmentation of allergic airway inflammation without requiring direct activation of mast cells with dsRNA or involvement of leukotriene B4 or prostaglandin D2 . [ABSTRACT FROM AUTHOR]- Published
- 2013
- Full Text
- View/download PDF
6. Impact of treatment with bevacizumab beyond disease progression: a randomized phase II study of docetaxel with or without bevacizumab after platinum-based chemotherapy plus bevacizumab in patients with advanced nonsquamous non-small cell lung cancer (WJOG 5910L)
- Author
-
Takeda, Masayuki, Okamoto, Isamu, Yamanaka, Takeharu, Nakagawa, Kazuhiko, and Nakanishi, Yoichi
- Subjects
SMALL cell lung cancer ,BEVACIZUMAB ,CLINICAL trials ,ENDOTHELIAL growth factors ,HEALTH outcome assessment - Abstract
Background: Bevacizumab, a humanized antibody to vascular endothelial growth factor (VEGF), shows clinical activity against human cancer, with its addition to standard chemotherapy having been found to improve outcome in patients with advanced nonsquamous non-small cell lung cancer (NSCLC). However, there have been no evidence-based studies to support the continued use of bevacizumab beyond disease progression in such patients treated with the drug in first-line therapy. We have now designed a randomized phase II trial to examine the clinical benefit and safety of continued bevacizumab treatment in patients with advanced nonsquamous NSCLC whose disease has progressed after first-line treatment with bevacizumab plus a platinum-based doublet.Methods/Design: WJOG 5910L was designed as a multicenter, open-label, randomized, phase II trial by the West Japan Oncology Group of docetaxel (arm A) versus docetaxel plus bevacizumab (arm B) in patients with recurrent or metatstatic nonsquamous NSCLC whose disease has progressed after first-line treatment with bevacizumab plus a platinum-based doublet. Patients in arm A will receive docetaxel at 60 mg/m2 and those in arm B will received ocetaxel at 60 mg/m2 plus bevacizumab at 15 mg/kg, with each drug administered on day 1 every 21 days until progression or unacceptable toxicity. The primary endpoint of the study is progression-free survival, with secondary endpoints including response rate, overall survival, and safety, for patients treated in either arm.Trial registration: UMIN (University Hospital Medical Information Network in Japan) 000004715 [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
7. Small interfering RNA against CD86 during allergen challenge blocks experimental allergic asthma.
- Author
-
Asai-Tajiri, Yukari, Matsumoto, Koichiro, Fukuyama, Satoru, Kan-O, Keiko, Nakano, Takako, Tonai, Ken, Ohno, Tatsukuni, Azuma, Miyuki, Inoue, Hiromasa, and Nakanishi, Yoichi
- Subjects
ASTHMA prevention ,CYTOKINES ,DENDRITIC cells ,ALBUMINS ,BIOLOGICAL models ,RESEARCH ,ASTHMA ,IMMUNOGLOBULINS ,CELL culture ,LUNGS ,BODY fluids ,ANIMAL experimentation ,BRONCHOCONSTRICTION ,RESEARCH methodology ,SMALL interfering RNA ,IMMUNOLOGY technique ,TISSUE culture ,EVALUATION research ,COMPARATIVE studies ,GENES ,T cells ,PULMONARY eosinophilia ,GENETIC techniques ,BRONCHIAL diseases ,PHENOTYPES ,MICE - Abstract
Background: CD86-CD28 interaction has been suggested as the principal costimulatory pathway for the activation and differentiation of naïve T cells in allergic inflammation. However, it remains uncertain whether this pathway also has an essential role in the effector phase. We sought to determine the contribution of CD86 on dendritic cells in the reactivation of allergen-specific Th2 cells.Methods: We investigated the effects of the downregulation of CD86 by short interfering RNAs (siRNAs) on Th2 cytokine production in the effector phase in vitro and on asthma phenotypes in ovalbumin (OVA)-sensitized and -challenged mice.Results: Treatment of bone marrow-derived dendritic cells (BMDCs) with CD86 siRNA attenuated LPS-induced upregulation of CD86. CD86 siRNA treatment impaired BMDCs' ability to activate OVA-specific Th2 cells. Intratracheal administration of CD86 siRNA during OVA challenge downregulated CD86 expression in the airway mucosa. CD86 siRNA treatment ameliorated OVA-induced airway eosinophilia, airway hyperresponsiveness, and the elevations of OVA-specific IgE in the sera and IL-5, IL-13, and CCL17 in the bronchoalveolar lavage fluid, but not the goblet cell hyperplasia.Conclusion: These results suggest that local administration of CD86 siRNA during the effector phase ameliorates lines of asthma phenotypes. Targeting airway dendritic cells with siRNA suppresses airway inflammation and hyperresponsiveness in an experimental model of allergic asthma. [ABSTRACT FROM AUTHOR]- Published
- 2014
- Full Text
- View/download PDF
8. Mast cells contribute to double-stranded RNA-induced augmentation of airway eosinophilia in a murine model of asthma.
- Author
-
Kan-O, Keiko, Matsunaga, Yuko, Fukuyama, Satoru, Moriwaki, Atsushi, Hirai-Kitajima, Hiroko, Yokomizo, Takehiko, Aritake, Kosuke, Urade, Yoshihiro, Nakanishi, Yoichi, Inoue, Hiromasa, and Matsumoto, Koichiro
- Abstract
Background: Clinical studies showed the contribution of viral infection to the development of asthma. Although mast cells have multiple roles in the pathogenesis of allergic asthma, their role of in the virus-associated pathogenesis of asthma remains unknown. Most respiratory viruses generate double-stranded (ds) RNA during their replication. dsRNA provokes innate immune responses. We recently showed that an administration of polyinocinic polycytidilic acid (poly IC), a mimetic of viral dsRNA, during allergen sensitization augments airway eosinophilia and hyperresponsiveness in mice via enhanced production of IL-13.Methods: The effect of poly IC on allergen-induced airway eosinophilia was investigated for mast cell-conserved Kit+/+ mice and -deficient KitW/KitW-v mice. The outcome of mast cell reconstitution was further investigated.Results: Airway eosinophilia and IL-13 production were augmented by poly IC in Kit+/+ mice but not in KitW/KitW-v mice. When KitW/KitW-v mice were reconstituted with bone marrow-derived mast cells (BMMCs), the augmentation was restored. The augmentation was not induced in the mice systemically deficient for TIR domain-containing adaptor-inducing IFN-β (TRIF) or interferon regulatory factor (IRF)-3, both mediate dsRNA-triggered innate immune responses. The augmentation was, however, restored in KitW/KitW-v mice reconstituted with TRIF-deficient or IRF-3-deficient BMMCs. Although leukotriene B4 and prostaglandin D2 are major lipid mediators released from activated mast cells, no their contribution was shown to the dsRNA-induced augmentation of airway eosinophilia.Conclusions: We conclude that mast cells contribute to dsRNA-induced augmentation of allergic airway inflammation without requiring direct activation of mast cells with dsRNA or involvement of leukotriene B4 or prostaglandin D2. [ABSTRACT FROM AUTHOR]- Published
- 2013
- Full Text
- View/download PDF
9. Depletion of club cells attenuates bleomycin-induced lung injury and fibrosis in mice.
- Author
-
Yokoyama T, Yanagihara T, Suzuki K, Hamada N, Tsubouchi K, Ogata-Suetsugu S, Mikumo H, Ikeda-Harada C, Maeyama T, Kuwano K, and Nakanishi Y
- Abstract
Background: The role of bronchiolar epithelial cells in the pathogenesis of pulmonary fibrosis has not been clarified. We previously demonstrated DNA damage in murine bronchioles in the early stages of bleomycin-induced pulmonary fibrosis that subsequently extended to alveolar cells at the advanced stages of the disease. Club cells are progenitor cells for bronchioles and are known to play protective roles against lung inflammation and damage. The aim of the present study was to elucidate the role of club cells in the development of pulmonary fibrosis., Methods: C57BL/6 J mice received naphthalene intraperitoneally on day -2 to deplete club cells and were given intratracheal bleomycin or a vehicle on day 0. Lung tissues were obtained on days 1, 7, and 14, and bronchoalveolar lavage was performed on day 14. Bronchiolar epithelial cells sampled by laser capture microdissection were analyzed by gene expression microarray analysis on day 14., Results: Club cell depletion induced by naphthalene protected mice from bleomycin-induced lung injury and fibrosis. Bleomycin-triggered bronchiolar TGF-β1 expression was reduced. Gene expression microarray analysis revealed that genes associated with inflammatory response and chemokine activity were downregulated in the bleomycin-injured bronchiolar epithelium with club cell injury compared to that in bronchiolar epithelium without cell injury., Conclusions: Club cells are involved in the development of lung injury and fibrosis.
- Published
- 2017
- Full Text
- View/download PDF
10. Effects of corticosteroid plus long-acting beta 2 -agonist on the expression of PD-L1 in double-stranded RNA-induced lung inflammation in mice.
- Author
-
Hamano S, Matsumoto K, Tonai K, Fukuyama S, Kan-O K, Seki N, Inoue H, and Nakanishi Y
- Abstract
Background: Airway viral infections cause the exacerbations of asthma and chronic obstructive pulmonary disease. PD-L1, also known as B7-H1, is an immune-checkpoint molecule that plays a role in an escape mechanism of viruses from the host immune systems. This escape may be associated with the persistence of viral infection and the exacerbation of the underlying diseases. In a study in vitro, we have shown that corticosteroids plus long-acting beta
2 -agonists (LABAs) attenuate the upregulation of PD-L1 on airway epithelial cells stimulated with an analog of viral double-stranded RNA, polyinosinic-polycytidylic acid (poly I:C). To address its biological relevance in vivo, we investigated the effect of corticosteroid plus LABA on the expression of PD-L1 in double-stranded RNA-induced lung inflammation in mice., Methods: Mice were intratracheally administered with poly I:C. The expression of PD-L1 on the lung cells was assessed by flow cytometry and inflammation was assessed for bronchoalveolar lavage fluid (BALF). Independent as well as combination effects of ciclesonide and indacaterol were examined., Results: Administration of low dose poly I:C upregulated the expression of PD-L1, induced neutrophilia and increased keratinocyte-derived chemokine (KC), macrophage inflammatory protein-1β (MIP-1β), and IL-6 in BALF. The upregulation of PD-L1, neutrophilic inflammation and increase of KC were suppressed by ciclesonide plus indacaterol, but not by either when administered independently. Although the upregulation of PD-L1 by high dose poly I:C was suppressed by ciclesonide plus indacaterol, neutrophilia and increased KC, MIP-1β, and IL-6 in BALF were not attenuated., Conclusions: Ciclesonide plus indacaterol attenuate double-stranded RNA-induced upregulation of PD-L1 in the lungs.- Published
- 2017
- Full Text
- View/download PDF
11. Methylenetetrahydrofolate reductase polymorphisms and interaction with smoking and alcohol consumption in lung cancer risk: a case-control study in a Japanese population.
- Author
-
Kiyohara C, Horiuchi T, Takayama K, and Nakanishi Y
- Subjects
- Aged, Alleles, Asian People genetics, Case-Control Studies, Female, Genotype, Humans, Japan epidemiology, Lung Neoplasms epidemiology, Male, Middle Aged, Risk Assessment, Alcohol Drinking adverse effects, Lung Neoplasms genetics, Methylenetetrahydrofolate Reductase (NADPH2) genetics, Polymorphism, Genetic, Smoking adverse effects
- Abstract
Background: Cigarette smoking is an established risk factor of lung cancer development while the current epidemiological evidence is suggestive of an increased lung cancer risk associated with alcohol consumption. Dietary folate, which is present in a wide range of fresh fruits and vegetables, may be a micronutrient that has a beneficial impact on lung carcinogenesis. Methylenetetrahydrofolate reductase (MTHFR) plays a crucial role in regulating folate metabolism, which affects both DNA synthesis/repair and methylation. We examined if smoking or alcohol consumption modify associations between MTHFR polymorphisms and lung cancer risk., Methods: We evaluated the role of the MTHFR C677T (rs1801133) and A1298C (rs1801131) polymorphisms in a case-control study comprised of 462 lung cancer cases and 379 controls in a Japanese population. Logistic regression was used to assess the adjusted odds ratios (OR) and 95% confidence intervals (95% CI)., Results: The TT genotype of the C677T polymorphism was significantly associated with an increased risk of lung cancer (OR = 2.27, 95% CI = 1.42 - 3.62, P < 0.01) while the A1298C polymorphism was not associated with lung cancer risk. The minor alleles of both polymorphisms behaved in a recessive fashion. The highest risks were seen for 677TT-carriers with a history of smoking or excessive drinking (OR = 6.16, 95% CI = 3.48 - 10.9 for smoking; OR = 3.09, 95% CI = 1.64 - 5.81 for drinking) compared with C-carriers without a history of smoking or excessive drinking, but no interactions were seen. The 1298CC genotype was only associated with increased risk among non-smokers (P < 0.05), and smoking was only associated with increased risks among 1298A-carriers (P < 0.01), but no significant interaction was seen. There was a synergistic interaction between the A1298C polymorphism and drinking (P < 0.05). The highest risk was seen for the CC-carriers with excessive drinking (OR = 7.24, 95% CI = 1.89 - 27.7) compared with the A-carriers without excessive drinking)., Conclusions: The C677T polymorphism was significantly associated with lung cancer risk. Although the A1298C polymorphism was not associated with lung cancer risk, a significant interaction with drinking was observed. Future studies incorporating data on folate intake may undoubtedly lead to a more thorough understanding of the role of the MTHFR polymorphisms in lung cancer development.
- Published
- 2011
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.